KYBELLA® is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness. KYBELLA® allows you to further expand your aesthetic injectable portfolio and offerings to your patients.
The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. Once the aesthetic response is achieved with KYBELLA®, retreatment is not expected.1
KYBELLA® is supplied in a pack of 4 single patient use 2 mL vials. KYBELLA® is administered by subcutaneous injections into submental fat in approximately 0.2 mL per injection spaced 1 cm apart using a 30G or smaller needle.
Patients asking about their submental fullness may, at times, refer to it as their “double chin.” It is a common, yet undertreated facial aesthetic condition that can:
- Detract from an otherwise balanced and harmonious facial appearance1
- Lead to an older and heavier look2
- Impact a broad range of adults, including both women and men
- Be caused by aging, genetics and/or weight gain3
According to a 2015 survey by the American Society for Dermatologic Surgery (ASDS), 67% of consumers are bothered by submental fullness—nearly as many as those bothered by lines and wrinkles around the eyes (69%).4
Unretouched photos of clinical trial patient taken before and after treatment with KYBELLA®.
BMI (before): 19.7 kg/m2
BMI (after): 20.4 kg/m2
Individual results may vary.